NVCT Earnings Nuvectis Pharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–22 of 22
| Q2 2026 | 2026-06-30 | -0.56 | 2026-08-04 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.26 | 2026-05-05 | 10-Q |
| FY 2025 | 2025-12-31 | -1.32 | 2026-02-11 | 10-K |
| Q3 2025 | 2025-09-30 | -1.01 | 2025-11-04 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.56 | 2026-08-04 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.27 | 2026-05-05 | 10-Q |
| FY 2025 | 2024-12-31 | -1.11 | 2026-02-11 | 10-K |
| Q3 2025 | 2024-09-30 | -0.75 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.51 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.25 | 2025-05-06 | 10-Q |
| FY 2024 | 2023-12-31 | -1.43 | 2025-02-25 | 10-K |
| Q3 2024 | 2023-09-30 | -1.02 | 2024-11-05 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.65 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.27 | 2024-05-07 | 10-Q |
| FY 2023 | 2022-12-31 | -1.51 | 2024-03-05 | 10-K |
| Q3 2023 | 2022-09-30 | -1.03 | 2023-11-08 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.59 | 2023-08-09 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.32 | 2023-05-10 | 10-Q |
| FY 2022 | 2021-12-31 | -3.02 | 2023-03-08 | 10-K |
| Q3 2022 | 2021-09-30 | -2.54 | 2022-11-08 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.48 | 2022-08-10 | 10-Q |
| Q1 2022 | 2021-03-31 | 0.01 | 2022-05-12 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.